SMA - TREATMENT: EP.284 SUNFISH Part 2: 24-month efficacy and safety of risdiplam in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA)

Autor: Nascimento, A., Day, J., Deconinck, N., Mazzone, E., Oskoui, M., Saito, K., Vuillerot, C., Baranello, G., Boespflug-Tanguy, O., Goemans, N., Kirschner, J., Kostera-Pruszczyk, A., Servais, L., Gerber, M., Gorni, K., Martin, C., Scalco, R., Staunton, H., Yeung, W., Mercuri, E.
Zdroj: In Neuromuscular Disorders October 2021 31 Supplement 1:S136-S136
Databáze: ScienceDirect
Externí odkaz: